Nutriband Inc
NTRB7.490USD
+0.100+1.35%
Market hours （ET）Quotes delayed by 15 min
82.95MMarket Cap
LossP/E TTM
More Details of Nutriband Inc Company
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Company Info
Ticker SymbolNTRB
Company nameNutriband Inc
IPO dateJun 20, 2017
CEOMr. Gareth Sheridan
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJun 20
Address121 S Orange Ave Ste 1500
CityORLANDO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code32801-3241
Phone14073776695
Websitehttps://nutriband.com/
Ticker SymbolNTRB
IPO dateJun 20, 2017
CEOMr. Gareth Sheridan
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Gareth Sheridan
Mr. Gareth Sheridan
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
1.76M
--
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Secretary
Chairman of the Board, President, Secretary
820.42K
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
17.21K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
1.17K
--
Mr. Sergei Glinka
Mr. Sergei Glinka
Independent Director
Independent Director
--
--
Prof. Dr. Stefani C. Mancas
Prof. Dr. Stefani C. Mancas
Independent Director
Independent Director
--
--
Dr. Alan Smith, Ph.D.
Dr. Alan Smith, Ph.D.
Chief Operating Officer, President of 4P Therapeutics
Chief Operating Officer, President of 4P Therapeutics
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Gareth Sheridan
Mr. Gareth Sheridan
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
1.76M
--
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Secretary
Chairman of the Board, President, Secretary
820.42K
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
17.21K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Sale of goods
667.43K
0.00%
Services
0.00
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
667.43K
100.00%
Non-United States
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Sale of goods
667.43K
0.00%
Services
0.00
0.00%
Shareholding Stats
Updated: Sun, Jul 20
Updated: Sun, Jul 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Botgros (Vitalie)
27.68%
TII Jet Services, LDA
16.21%
Sheridan (Gareth)
15.79%
Glinka (Serguei)
7.40%
Melnik (Serguei)
7.36%
Other
25.57%
Shareholders
Shareholders
Proportion
Botgros (Vitalie)
27.68%
TII Jet Services, LDA
16.21%
Sheridan (Gareth)
15.79%
Glinka (Serguei)
7.40%
Melnik (Serguei)
7.36%
Other
25.57%
Shareholder Types
Shareholders
Proportion
Individual Investor
60.16%
Corporation
16.21%
Investment Advisor
2.09%
Investment Advisor/Hedge Fund
0.83%
Research Firm
0.12%
Other
20.59%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
44
8.86M
79.41%
+467.78K
2025Q1
43
8.13M
73.14%
+1.78M
2024Q4
40
8.04M
72.39%
+1.68M
2024Q3
40
8.08M
72.79%
+1.82M
2024Q2
38
5.19M
52.25%
+2.18M
2024Q1
34
4.36M
55.65%
+1.38M
2023Q4
30
4.30M
54.90%
+1.31M
2023Q3
29
2.96M
37.78%
-39.44K
2023Q2
28
2.95M
37.71%
-29.57K
2023Q1
28
2.96M
37.92%
-64.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Botgros (Vitalie)
3.09M
27.68%
+716.50K
+30.22%
Apr 25, 2025
TII Jet Services, LDA
1.81M
16.21%
+485.05K
+36.66%
Sep 01, 2024
Sheridan (Gareth)
1.76M
15.79%
-103.00
-0.01%
Apr 25, 2025
Glinka (Serguei)
825.00K
7.4%
--
--
Apr 25, 2025
Melnik (Serguei)
820.42K
7.36%
--
--
Apr 25, 2025
The Vanguard Group, Inc.
199.03K
1.78%
+74.44K
+59.75%
Mar 31, 2025
Goodman (Gerald)
86.33K
0.77%
--
--
Apr 25, 2025
Geode Capital Management, L.L.C.
63.55K
0.57%
+1.11K
+1.79%
Mar 31, 2025
Smith (Allan)
41.91K
0.38%
-6.99K
-14.29%
Apr 25, 2025
Patrick (Jeff)
36.61K
0.33%
--
--
Apr 25, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 29, 2022
Split
6>7
Date
Type
Ratio
Jul 29, 2022
Split
6>7
